Invivyd completes enrollment in Phase 3 LIBERTY trial of VYD2311 antibody vs mRNA COVID vaccine
PUBT · 06/16 11:03
Share
Listen to the news
- Invivyd completed enrollment in its Phase 3 LIBERTY trial comparing VYD2311 antibody prophylaxis with an mRNA COVID-19 vaccine.
- Topline results have not been presented; initial data are expected in Q3 2026, potentially alongside the pivotal DECLARATION readout.
- The study aims to show whether VYD2311 delivers better tolerability than vaccination, supporting positioning as a vaccine alternative if cleared.
- LIBERTY also evaluates safety when VYD2311 is given with an mRNA vaccine, informing real-world use and regulatory discussions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Invivyd Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606160701PRIMZONEFULLFEED9747364) on June 16, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved